Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects

Diabetes, Obesity and Metabolism

Volumn 16, Issue 3, 2014, Pages 268-272

  Garg, R ^a   Kneen, L ^a   Williams, G H ^a   Adler, G K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endothelial function; Insulin resistance; Mineralocorticoid receptor; Obesity

Indexed keywords

ALDOSTERONE; INSULIN; PLACEBO; SPIRONOLACTONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL FUNCTION; FEMALE; FLOW MEDIATED VASODILATATION; HOMEOSTATIC MODEL ASSESSMENT; HUMAN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PERFUSION; RANDOMIZED CONTROLLED TRIAL; RENAL PLASMA PERFUSION; SYSTOLIC BLOOD PRESSURE; VASODILATATION; YOUNG ADULT;

ENDOTHELIAL FUNCTION; INSULIN RESISTANCE; MINERALOCORTICOID RECEPTOR; OBESITY;

ADOLESCENT; ADULT; ALDOSTERONE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; BRACHIAL ARTERY; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OBESITY; SPIRONOLACTONE; TREATMENT OUTCOME; VASODILATION;

EID: 84893772499     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12224     Document Type: Article

References (29)

1. Available from URL: http://www.cdc.gov/obesity/data/adult.html. Accessed 20 August 2013.
2. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-2850.
3. Bentley-Lewis R, Adler GK, Perlstein T et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92: 4472-4475.
4. Rossi GP, Belfiore A, Bernini G et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93: 2566-2571.
5. Andronico G, Cottone S, Mangano MT et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001; 25: 239-242.
6. Garg R, Adler GK. Role of mineralocorticoid receptor in insulin resistance. Curr Opin Endocrinol Diabetes Obes 2012; 19: 168-175.
7. Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes 2013; 62: 313-319.
8. Han SY, Kim CH, Kim HS et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
9. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3 T3-L1 adipocytes. Endocrinology 2009; 150: 1662-1669.
10. Hirata A, Maeda N, Hiuge A et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-172.
11. Guo C, Ricchiuti V, Lian BQ et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261.
12. Kuster GM, Kotlyar E, Rude MK et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111: 420-427.
13. Guo C, Martinez-Vasquez D, Mendez GP et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006; 147: 5363-5373.
14. Wada T, Kenmochi H, Miyashita Y et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010; 151: 2040-2049.
15. Catena C, Lapenna R, Baroselli S et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006; 91: 3457-3463.
16. Abiose AK, Mansoor GA, Barry M, Soucier R, Nair CK, Hager D. Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am J Cardiol 2004; 93: 1564-1566.
17. Garg R, Kumbkarni Y, Aljada A et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000; 36: 430-435.
18. Fisher ND, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 1999; 56: 635-641.
19. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
20. Pojoga LH, Baudrand R, Adler GK. Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity. Eur Heart J 2013; 34: 3475-3477.
21. Nagase M, Fujita T. Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol 2013; 9: 86-98.
22. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597.
23. Luther JM, Luo P, Kreger MT et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011; 54: 2152-2163.
24. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010; 12: 252-257.
25. Radikova Z, Koska J, Huckova M et al. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 2006; 114: 249-256.
26. Homma T, Fujisawa M, Arai K, Ishii M, Sada T, Ikeda M. Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. J Vet Med Sci 2012; 74: 1015-1022.
27. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007; 92: 2552-2558.
28. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004; 47: 1687-1694.
29. Hamdy O, Ledbury S, Mullooly C et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119-2125.